Lung Cancer Market - By Diagnostics and Therapeutics, By Indication, By End Use - Global Forecast, 2025 – 2034

Lung Cancer Market Size

The global lung cancer market size was estimated at USD 35.1 billion in 2024. The market is expected to grow from USD 38.4 billion in 2025 to USD 95.1 billion in 2034, at a CAGR of 10.6% during the forecast period. High growth is attributed to the increasing prevalence of lung cancer, government initiatives for cancer awareness and rising patient assistance programs (PAPs), among others.
 

Moreover, growing healthcare expenditure focused on cancer treatment by the major players has resulted into increasing research and development activities for discovering, developing and manufacturing novel cancer drugs. Additionally, the growing number of potential medicines in the pipeline is expected to increase the adoption of diagnostics and treatment for lung cancer, thereby fostering market growth.  
 

Furthermore, the market is bolstered by growing advancements in novel drug delivery systems and ongoing cancer research which have significantly improved the efficacy of lung cancer treatments. For instance, companies such as AstraZeneca, Roche, and Bristol-Myers Squibb are investing heavily in next-generation lung cancer treatments. In 2024, there were over 1,000 clinical trials focusing on lung cancer therapies globally. Additionally, the development of new formulations coupled with ongoing research and development activities, contributing to market growth. The identification of biomarkers (such as PD-L1 expression) has enabled precision medicine, boosting demand for advanced diagnostics and personalized treatments, which drives market growth.
 

The rising trend of aging population globally increasing the risk of lung cancer especially in countries such as Japan, Germany, and U.S., leads to higher patient pool, that further contribute to market growth. For instance, as per the American Cancer Society report, lung cancer prevalence increases significantly with age, particularly after 50. The average age of diagnosis in the U.S. is around 70. While some lung cancer cases occur in individuals younger than 50, the vast majority are diagnosed in older adults, especially those 65 and older. In addition, the increasing smoking rates in low-and middle-income countries, leads to higher incidence of lung cancer, that further contributes to market growth.  
 

Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. This growth can spread beyond lungs by the process of metastasis into nearby tissue or other parts of the body. Lung cancers usually are grouped into two main types called small cell and non-small cell. These types of lung cancer grow differently and are treated differently.
 

Lung Cancer Market Trends

• The rising advancement in targeted therapies, immunotherapies, and personalized medicine have enhanced the treatment efficacy by improving the patient outcomes. In addition, the development of innovative drugs such as pembrolizumab (Keytruda) for the treatment of non-small cell lung cancer (NSCLC) contribute to the growth of the market.
   
• As an example of this, the U.S. Food and Drug Administration (FDA) approved pembrolizumab in January 2023 for the adjuvant treatment of stage IB, II, or IIIA NSCLC following resection and platinum-based chemotherapy. Thus, the ongoing research and development activities, with increasing investment lead to the development of novel therapies, that boost market growth.
   
• Moreover, the increasing research and development activities funded by various government and private organizations for the development of advanced diagnostics tools and novel therapeutics for treatment, drives the growth of the market. In addition, approvals of new drugs by regulatory bodies coupled with supportive government policies, facilitate market growth.
   
• The rising healthcare expenditure, increased insurance coverage, and availability of advanced healthcare infrastructure equipped with technologically advanced diagnostics devices are facilitating early diagnosis of disease. The early diagnosis of disease increases the patient pool for lung cancer, thereby raises demand for effective therapeutics, that contribute to market growth.
   
• Additionally, the increasing awareness of personalized medicine and biomarker testing for lung cancer leads to rising demand for genetic profiling such as epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene (KRAS), anaplastic lymphoma kinase (ALK mutation).
   
• Thus, the increasing adoption of precision medicine enables the selection of optimal therapies, improving clinical outcomes, thereby raising demand for targeted drugs, that is anticipated to drive the market growth.
   
• Lastly, the growing adoption of telemedicine and digital health such as tele-oncology platforms are enhancing patient engagement, enabling remote consultation, and supporting post-treatment monitoring, especially vital in rural and under-resourced areas, spur market growth during the analysis period.
   

Trump Administration Tariffs

• The reciprocal Trump tariffs on Chinese goods such as medical diagnostic equipment and electronic components imposed may increase the cost of raw materials and lung cancer monitoring technologies. Though trump administration have exempted pharmaceutical drugs from reciprocal tariffs. These tariffs can also trigger supply chain disruptions, as many lung cancer solution providers rely heavily on Chinese manufacturers for affordable imaging systems, biopsy tools, and diagnostic sensors.
   
• As a result, companies in the lung cancer diagnostics and therapeutics market may need to reevaluate and restructure their sourcing and manufacturing strategies to reduce reliance on Chinese suppliers. This could lead to a strategic shift toward alternative sourcing hubs such as India, Vietnam, and Eastern Europe.
   
• In the short term, the industry may face product availability delays, higher operational costs due to vendor diversification, and potential interruptions in after-sales support for imaging systems, molecular diagnostics platforms, and therapeutic devices.    
   
• While large multinationals may absorb these additional costs or diversify more easily, smaller and mid-sized companies in the lung cancer diagnostics or therapeutics space may struggle to maintain margins, potentially stalling innovation and reducing competitive intensity in the market.
   

Lung Cancer Market Analysis

In 2021, the global market was valued at USD 26.1 billion. The following year, it saw a slight increase to USD 28.8 billion, and by 2023, the market further climbed to USD 31.7 billion.
 

Based on diagnostics and therapeutics, the global market is divided into diagnostics and therapeutics. The therapeutics segment is further sub-segmented into non-invasive therapy and minimally invasive therapy. The therapeutics segment dominated the market and was valued at USD 18.7 billion in 2024.
 

• The therapeutics segment dominated the market owing to growing adoption of cancer immunotherapy and targeted therapy for the treatment of lung cancer as they are more effective, convenient, and have limited side-effects as compared to traditional chemotherapy.
   
• Additionally, the growing awareness among the population regarding the benefits of the immunotherapy, hormonal therapy, and targeted therapy is largely driving the demand for novel cancer therapeutics amongst the global lung cancer patients.
   
• Moreover, the growing adoption of combination therapies such as chemotherapy along with immunotherapy or dual-targeted therapies, are gaining market share.
   
• Immune checkpoint inhibitors such as pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq) have transformed treatment protocols for both early-stage and advanced NSCLC and small cell lung cancer (SCLC). These therapies are increasingly used as first-line or adjuvant treatments, that drives the growth of the market.
   

Based on the indication, the global lung cancer market is categorized into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment accounted for the highest market share of 82.7% in 2024.
 

• The presence of a strong pipeline for NSCLC is projected to propel the segment growth over the coming years. For instance, Merck & Co. Inc comprises several pipeline drugs such as LENVIMA (MK-7902) and LYNPARZA (MK-7339) that are being investigated or in clinical phases for NSCLC.
   
• Thus, development of such advanced treatments for NSCLC indication is expected to drive the market during the forecast period.
   
• Furthermore, the rising incidence of lung cancer, particularly NSCLC, increases with age. As the global population ages, the number of NSCLC cases rises, contributing to the growth of the market.
   

Based on the end use, the global lung cancer market is categorized into hospitals, diagnostic laboratories, specialty cancer clinics, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 61.5 billion by 2034.
 

• High adoption rates for technologically developed bronchoscopy and other devices used in diagnosis of cancer is anticipated to surge the number of diagnoses conducted in hospital settings.
   
• Moreover, favorable reimbursement policies for several equipment and cancer treatment surgeries carried out in hospital settings is likely to boost the segment revenue.
   
• Additionally, the establishment of specialized cancer treatment centers and the expansion of hospital networks have improved access to care, attracting more patients. For instance, the Townsville University Hospital's newly established lung cancer clinic has effectively reduced wait times for treatment by two weeks, addressing the crucial need for swift intervention.
   
• Moreover, many hospitals engage in clinical trials that explore the efficacy of novel drug therapies in combination with other treatments. This research drives the growth of therapeutics drugs use in hospitals for lung cancer, as it contributes to improved therapeutic outcomes and potentially expands the market growth.
   

In 2024, the U.S. held a significant position in the North America lung cancer market and was valued at USD 15.4 billion.
 

• The rising incidence and prevalence of lung cancer in the U.S. along with approval of new products for the treatment of both non-small cell lung cancer and small cell lung cancer in the region is expected to boost the growth of North America market.
   
• Moreover, the easy availability of technologically advanced cancer diagnostic tools leads to early diagnosis of disease, that raises the count of the number of people diagnosed with lung cancer, thereby driving market growth.
   
• In addition, the favorable regulatory authority towards development of advanced treatment and government supportive research and development initiatives with the presence of key market players will contribute to market growth.
   
• Furthermore, the U.S. government, through various agencies such as the National Cancer Institute (NCI) and the National Institutes of Health (NIH), continues to invest heavily in cancer research, including lung cancer, by allocating substantial funding for clinical trials, drug development, and translational research initiatives aimed at improving early detection, treatment efficacy, and patient survival outcomes.
   

Germany lung cancer market shows strong growth potential in the Europe market.
 

• In Germany, lung cancer remains one of the most common cancers. New research shows that the incidence rates continue to grow for women. For example, one study looking at trends in lung cancer incidence in Germany noted the increasing trend in women as part of the overall market upsurge.
   
• Besides, Germany has also launched programs for the screening of lung cancer aimed at early diagnosis in vulnerable populations, such as smokers aged 55 to74. The ability to identify health conditions at an early stage greatly improves patient outcomes which contributes to increased treatment markets.
   
• In addition, the German health care system with its universal insurance coverage offers comprehensive payment for cancer treatment, including new immuno- and targeted therapies. This improves accessibility for patients and supports market growth.
   

The lung cancer market in Asia Pacific is estimated to grow at a CAGR of 11% over the next few years.
 

• The widespread use of tobacco is a significant risk factor. With over 300 million smokers in China, tobacco consumption remains a key driver for lung cancer incidence. The country accounts for about 40% of global cigarette consumption, significantly contributing to the rise in lung cancer cases that contribute to market growth.
   
• Moreover, the growing availability of targeted therapies and immunotherapies has boosted the lung cancer treatment market in China. Drugs such as Osimertinib, Pembrolizumab, and Nivolumab have been approved for the treatment of non-small cell lung cancer (NSCLC), providing more effective treatment options.
   
• Furthermore, China faces severe air pollution, especially in urban areas, which has been linked to a higher risk of lung cancer. Studies have shown that long-term exposure to air pollution can increase the risk of lung cancer, contributing to the rising burden of the disease.
   

Brazil's lung cancer market is projected to witness robust growth in Latin America market.
 

• Brazil is actively working toward providing comprehensive healthcare services to all citizens through the SUS (Sistema Unico de Saude) public health system. The treatment available for cancers, especially surgery, chemotherapy, and newer biologic drugs, is on the rise, positively influencing the market.
   
• Moreover, the elderly population of Brazil is associated with a higher prevalence of cancer. The chance of developing cancer, including lung cancer, increases with age. The incidence of people aged 60 years and above is growing, supporting the increase of cancer. 
   
• Moreover, Brazil has entered into agreements with international organizations to enhance the accessibility of technology and treatment for cancer. For instance, the country has improved its healthcare services for cancer patients through its partnerships with the World Health Organization (WHO) and GAVI.
   

Saudi Arabia lung cancer market is anticipated to grow in the Middle East and Africa market.
 

• Through Vision 2030, the Saudi government is spending more on healthcare, including the expansion of cancer care and treatment centers. This has increased access to advanced treatment and early diagnosis which increases the region’s market for lung cancer drugs and therapies.
   
• In addition, public education campaigns by the Saudi Cancer Society and the Ministry of Health have improved the understanding of lung cancer’s symptoms along with its detection and treatment. These campaigns have resulted in increased screening, fostering early diagnosis and greater reliance on cancer treatment services.
   
• Moreover, in Saudi Arabia, there is a growing acceptance of modern medical interventions as more people look for advanced solutions to cancer. This increases the adoption of advanced medicine which includes chemotherapy, immunotherapy and other targeted therapies, hence strengthening the market for lung cancer therapeutics.
   

Lung Cancer Market Share

The top 5 companies in the market, such as F. Hoffmann La Roche, Bristol-Myers Squibb, Merck, Pfizer, and Teva Pharmaceuticals accounting for approximately 60% of the market share. These companies maintain their dominance through innovations in diagnostic technologies, immunotherapies, and AI-assisted health management solutions, addressing the growing demand for specialized lung cancer care. The competitive landscape in the market is characterized by a mix of global pharmaceutical and biotechnology companies and regional players. Firms are expanding their portfolios with precision diagnostic tools, targeted therapies, and advanced treatment systems to enhance disease management and treatment precision.
 

For example, Johnson & Johnson, Amgen, AstraZeneca and various other key players are focusing on developing cutting-edge targeted therapies for lung cancer, offering comprehensive treatment solutions. Companies are investing in AI-driven analytics, real-time monitoring systems, and advanced therapeutic interventions, fueling market expansion and intensifying competition in the market.
 

Lung Cancer Market Companies

Prominent players operating in the lung cancer industry are as mentioned below:

• AdvaCare Pharma
• Biodesix
• Bristol-Myers Squibb Company
• CHEPLAPHARM Group
• Cleveland Clinic
• F. Hoffmann La Roche
• Memorial Sloan Kettering Cancer Center
• Merck
• Pfizer
• Rutgers Health Sun Pharmaceutical
• Sun Pharmaceuticals
• Teva Pharmaceuticals
• UPMC
• Weill Cornell Medicine 
   

To stay competitive, key players are investing in research and development, partnerships, and collaborations to launch novel therapeutic solutions for lung cancer treatment.
 

• Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved RYBREVANT plus LAZCLUZE for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
   
• In addition, iTeos and GSK initiate GALAXIES lung-301 phase 3 study, assessing Belrestotug and Dostarlimab in previously untreated, unresectable locally advanced / metastatic pd-l1 selected non-small cell lung cancer.
   
• Moreover, FDA approves Genentech's Alecensa as first adjuvant treatment for people with alk-positive early-stage lung cancer. The product approval was based on phase III ALINA study showing reduced risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC).
   

Lung Cancer Industry News

• In September 2024, the Food and Drug Administration approved Osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC). This approval aimed to broaden the treatment availability, complementing existing therapies for lung cancer.
   
• In August 2024, AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the U.S. for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC).
   
• In May 2024, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. This helped the company expand its product range for lung cancer.
   
• In May 2021, the FDA approved LUMAKRAS (sotorasib) for treating adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, highlighting regulatory support for innovative treatments. This helped the company expand its product range in the oncology sector.
   

The lung cancer market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Diagnostics and Therapeutics

• Diagnostics
  • Bronchoscopy
  • Molecular testing
  • Imaging
  • Other diagnostics
• Therapeutics
  • Non-invasive therapy
    • By type
      • Chemotherapy
      • Targeted therapy
      • Immunotherapy
      • Other non-invasive therapies
    • By route of administration
      • Oral
      • Parenteral
  • Minimally invasive therapy
    • Radiofrequency ablation  
    • Microwave ablation
    • Thermal/cryoablation
    • Other minimally invasive therapies

Market, By Indication

• Non-small cell lung cancer
• Small cell lung cancer

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Specialty clinics
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE